The tide of medical and health innovation is surging, and high-quality innovation projects are the core driving force of industry development and the focus of capital
On May 6th, the National Medical Products Administration (NMPA) officially approved the world’s first CDK2/4/6 inhibitor, Coumoxili Capsules (Saitanxin), independently developed by China’s biopharmaceutical subsidiary, Zhengda
This week, there are various hot topics in the financing of the medical and health field. Ganewei Medical’s multi hundred million yuan C-round enhanced tumor ablation
· Guangxi Holds Expert Review Meeting on Patent Regulations Revision · Lex Machina Releases 2026 Class Action Litigation Report · BMW's US Patent Dispute in Germany
Current biopharmaceutical financing updates: Nuanxin Jia has completed a strategic financing of 300 million yuan, leading the field of visual brain computer interfaces; Intelligent Diagnosis Technology’s
In the increasingly fierce competition for intellectual property, the speed of patent layout directly affects the market share advantage. For innovative enterprises, choosing the appropriate review
· Fujian Releases 2025 Provincial Intellectual Property Protection Typical Cases · Germany's Court Rules: AI-Generated Designs Not Protected by Copyright · USPTO Releases New Procedure for